By Robert King
Senate Majority Leader Mitch McConnell released a new COVID-19 legislative package that includes liability protection for providers.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Canada granted conditional approval to Gilead's remdesivir in severe COVID-19. Pfizer could earn $15 billion-plus from its COVID-19 vaccine, one analyst thinks; meanwhile, the pharma ratcheted up its 2020 sales projections, vaccine not included. A vaccine distribution initiative weighs tiered pricing for equitable shot access. Plus, a new viral mutation could boost vaccine efficacy.
read more
By Robert King
Federal stimulus funds helped Universal Health Services generate $251 million in profit in the second quarter and offset major declines in revenue due to COVID-19.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Angus Liu
Add another name to the list of pharmas reporting sales declines amid the pandemic. But this company, Pfizer, is still dialing up its full-year revenue expectations—not that it’s counting any contribution from a closely watched COVID-19 vaccine candidate it’s hoping to launch this year.
read more
By Paige Minemyer
Centene Corporation earned $1.21 billion in profit for the second quarter. That's a significant boost from the $495 million in profit it reported in the second quarter of 2019.
read more
By Ben Adams
Covance’s sales fell into the red this quarter as LabCorp’s CRO unit continues to battle major pandemic headwinds.
read more
.jpg/BioNTech_Headquarters%20(1).jpg/1af0e7b32ab97e0ea45ee68c0bc0856e)
